natgillin/translations-raw huggingface dataset:
The agonist for use according claim 1 wherein the a adrenergic agonist is selected from oxymetazoline, naphazoline, tetrahydrozoline, phenylephrine, xylometazoline, methoxamine, metaraminol, midodrine, desglymidodrine, cirazoline, amidephrine, brimonidine, clonidine, guanfacine, guanabenz, apraclonidine, xylazine, medetomidine, dexmedetomidine, a-methyldopa, and combinations thereof. 
Agonist za uporabu u skladu sa zahtjevom 3, naznačen time što je selektivni agonist alfa 1 adrenergijskog receptora odabran od oksimetazolina, nafazolina, tetrahidrozolina, fenilefrina, fenilefrin hidroklorida, ksilometazolina, metoksamina, metaraminola, midodrina, desglimidodrina, cirazolina, amidefrina i njihovih kombinacija.
calculating a reference statistical value of sizes of DNA molecules located in a reference region; 
utvrđivanja druge količine molekula DNK smještenih u drugoj regiji;
Photobioreactor for culturing photoautotrophic microorganisms according to claim 7 characterised in that the section is a straight section (70). Photobioreactor for culturing photoautotrophic microorganisms according to claim 8 characterised in that the straight section (70) has an annular bifurcation at its free end in the form of a drop (71). 
Fotobioreaktor za uzgajanje fotoautotrofnih mikroorganizama prema patentnom zahtjevu 5, naznačen time, da je odsječak ravni odsječak (70) i na svom slobodnom kraju ima ili prstenasto račvanje u obliku kaplje (71) ili završava kružnim proširenjem (72).
Chemistry of the Present Invention 
Kemija prikazanog izuma
Use of the compound of claim 1 in the manufacture of a medicament for the treatment of a B-amyloid disease or a synucleinopathy in a mammal suffering therefrom. 
Uporaba spoja prema zahtjevu 1 naznačena time da je za proizvodnju medikamenta za liječenje f-amiloidne bolesti ili sinukleinopatije kod sisavaca koji od njih pati.
• human antibody. 
* ljudsko protutijelo.
is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of-N(R1k)R1m; 
je atom vodika, halogen atom, hidroksil skupina, niža alkilna skupina ili skupina -N(R1k)R1m;
The apparatus of claim 5 the attachment points are screw bosses and wherein the turning vane including the screw bosses is formed in an extrusion mold. The apparatus of claim 1 further comprising a recess on the lower surface shaped to correspond to one end of the hollow turning vane. 
Sklop u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što dodatno ima udubljenje (232) na donjoj površini (233) takvog oblika da odgovara jednom kraju šuplje rotirajuće lopatice (201).
treating or preventing cancer metastasis in a subject, comprising administering to the subject a therapeutically effective amount of the compound or enantiomer, diastereomer, tautomer, or pharmaceutically-acceptable salt or solvate thereof. 
liječenju ili prevenciju metastaza raka u subjekta, koje obuhvaća primjenu terapijski učinkovite količine spoja formule VIII subjektu.
Crystalline methylthioninium chloride monohydrate as Form E having the following characteristic peaks in a powder X-ray diffraction pattern (using CuKa as the source of radiation, at a wavelength of 1.54180 Å): Peak 
Kristalni metiltioninium klorid monohidrat u Obliku E, naznačen time, da ima slijedeće karakteristične maksimume u difraktogramu rendgenske difrakcije praha (koristeći CuKa kao izvor radijacije, na valnoj duljimi od 5
The mixture is converted into pellets of the desired particle size by using an appropriate equipment (extruder-spheroidizator-drier, high-shear granulator-drier, rotofluidization apparatus). 
Smjesa se prevodi u granule željene veličine čestica pomoću odgovarajuće opreme (ekstruder-sferoidizator-sušionik, 'high-shear' granulator-sušionik, uređaj za rotacijsku fluidizaciju).
a protease inhibitor, a matrix metalloproteinase inhibitor, a methionine aminopeptidase inhibitor, e.g. bengamide or a derivative thereof, or a proteosome inhibitor, e.g. PS-341, and/or 
inhibitor telomeraze, poželjno telomestatin; x. inhibitor proteaze, inhibitor metaloproteinaze matriksa, inhibitor aminopeptidaze metionina, poželjno bengamid ili njegov derivat, ili inhibitor proteozoma, poželjno PS-341, i/ili xi.
Most preferably the aqueous preparation according to the invention contains a glycoPEGylated G-CSF as active agent, Polysorbate 20 and/or Polysorbate 80 as surfactant, sorbitol and/or mannitol as tonicity modifier, acetate as buffer and sodium, and no other excipients. 
Or s gdje je AA treonin 133, ili treonin 134 ako je prisutan N-terminalni metionin, od G-CSF, 1 gdje je f cijeli broj izabran između 1 do 2500, polisorbat 20 i/ili polisorbat 80 kao površinski aktivnu tvar (surfaktant), sorbitol i/ili manitol kao modifikatore toničnosti, acetat kao pufer i natrij, bez drugih pomoćnih tvari, pri čemu pripravak ima pH u rasponu od 4.5 do 5.5.
A method of treating a viral infection caused by a Flaviviridae virus comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or pharmaceutical composition of claim 1 . 
Tvar iz bilo kojeg od patentnih zahtjeva 1 do 3 za uporabu u metodi za liječenje virusne infekcije uzrokovane Flaviviridae virusom.
In another aspect, the formulation of the invention exhibits stability under storage at a temperature of −20±5° C. The formulation of the invention may exhibit stability under storage at a temperature of −20±5° C. for at least 2 weeks, 3 weeks, 4 weeks, 2 months, up to 3 months and more (preferably at least 6 months, at least 9 months, at least 1 year, 1.5 year or even 2 years or more). 
- manje od 10% polipeptida tvori dimere tijekom skladištenja na temperaturi od 37+5*C do najmanje 2 tjedna (poželjno najmanje 3 tjedna, najmanje 5 tjedana, najmanje 8 tjedana, najmanje 10 tjedana, najmanje 3 mjeseca, najmanje 6 mjeseci, najmanje 1 godinu, 1.5 godinu ili čak 2 godine ili više), te se % dimera mjeri pomoću SE-HPLC;
The use of claim 1, where the chemotherapeutic agent is erlotinib and the cancer is breast cancer. 
Uporaba prema zahtjevu 1, gdje je kemoterapijsko sredstvo erlotinib i rak je rak dojke.
Stirring continues for a further 2 hours after which time, the reaction mixture is quenched with water (2 ml) and is allowed to slowly warm to room temperature. 
Miješanje se nastavi daljnjih 2 sata, nakon čega se reakcijsku smjesu razrijedi s vodom (2 ml) i pusti se polako zagrijati na sobnu temperaturu.
The inlet valve 7 is formed by the first gasket 11, the first channel 9 and the first aperture 10 . 
Ulazni ventil 7 je oblikovan pomoću prve brtve 11, prvog kanala 9 1 prve rupice 10.
After 1983 part of arsenic was replaced with zinc. 
Nakon 1983. dio arsena je zamijenjen sa cinkom.
a product reader configured to determine at least one characteristic about contents of the cartridge responsive to analyzing the cartridge. 
identifikacijski marker (52) konfiguriran za pokazivanje barem jedne karakteristike sadržaja uloška (50).
The process according to claim 11 further comprising the use of a glidant to prepare a blend which is ready for tabletting. 
Postupak prema zahtjevu 12 ili 13, naznačen time, da nadalje obuhvaća uporabu kliznog sredstva za pripravljanje smjese koja je spremna za tabletiranje.
A sample of the reaction mixture was filtered over celite and the filtrate was concentrated under reduced pressure. 
Uzorak reakcijske smjese filtira se preko Celite*-a, a filtrat koncentrira pod sniženim tlakom.
The humanized CD37-specific binding protein or the CD20-specific binding protein or the article of manufacture for use in treating a B-cell cancer or an autoimmune disease of claims 1, 2 or 3, wherein the light chain CDR1, CDR2, and CDR3 of the humanized CD37-specific binding protein consists of the amino acid sequences of SEQ ID NOS: 61, 64 and 66, respectively; and wherein the heavy chain CDR1, CDR2, and CDR3 consists of the amino acid sequences of SEQ ID NOS: 63, 65 and 67 respectively. 
Humanizirani CD37-specifični vezni protein u skladu s patentnim zahtjevom 1, pri čemu se CDR1, CDR2 i CDR3 lakog lanca sastoje od sljedova aminokiselina SEQ ID NOS: 61, 64 i 66, redom; i pri čemu se CDR1, CDR2 i CDR3 teškog lanca sastoje od sljedova aminokiselina SEQ ID NOS: 63, 65 i 67, redom.
In some embodiments, the antibody or antibody fragment blocks binding of human PD-L1 and human PD-L2 to human PD-1. 
PATENTNI ZAHTJEVI 1. Antitijelo ili fragment antitijela koje/koji se veže za humani PD-1, koji sadrži:
The diabody molecule of claim 13, wherein the tumor-associated antigen is a breast cancer antigen, an ovarian cancer antigen, a prostate cancer antigen, a cervical cancer antigen, a pancreatic carcinoma antigen, a lung cancer antigen, a bladder cancer antigen, a colon cancer antigen, a testicular cancer antigen, a glioblastoma cancer antigen, an antigen associated with a B cell malignancy, an antigen associated with multiple myeloma, an antigen associated with non-Hodgkin's lymphoma, or an antigen associated with chronic lymphocytic leukemia. 
Molekula diatijela prema zahtjevu 13, naznačena time što antigen povezan s tumorom je antigen karcinoma dojke, antigen karcinoma jajnika, antigen karcinoma prostate, antigen karcinoma vrata maternice, antigen karcinoma gušterače, antigen karcinoma pluća, antigen karcinoma mjehura. antigen karcinoma debelog crijeva, antigen karcinoma testisa, antigen karcinoma glioblastoma, antigen povezan s malignitetom B stanica, antigen povezan s multiplim mijelomom, antigen povezan s ne-Hodgkinovim limfomom, ili antigen povezan s kroničnom limfocitnom leukemijom. Molekula diatijela prema zahtjevu 13, naznačena time što antigen povezan s tumorom je A33; ADAM-9; ALCAM;
In particular embodiments, the compound is (4-cyclopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone citrate salt dihydrochloride or (4-cyclopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone citrate salt. 
Spoj u skladu sa zahtjevom 1, naznačen time, da je (4-ciklopropil-piperazin-1-il)-(4-tiomorfolin-4-ilmetil-fenil)- metanon ili njegov enantiomer, hidrat, solvat ili farmaceutski prihvatljiva sol.
In some embodiments, the pharmaceutical composition is one comprising a therapeutically effective concentration of a PRG4 inducing compound and a PRG4 protein. 
Farmaceutski oblik za uporabu prema zahtjevu 1 ili 2, gdje farmaceutski oblik sadrži PRG4 u terapijski učinkovitoj koncentraciji od 10-10,000 ug/mL.
A method according to one or more of claims 1 to 8, wherein Service Information, SI, tables are transmitted on said pseudo-streams (3c,3d), said tables containing information necessary for knowing the frequency positions of the channels bonded together for transmitting said data stream (3) and for identifying a master channel. 
Metoda prema jednom ili više od patentnih zahtjeva 1 do 8, gdje su tabele servisnih informacija, SI, prenesene na navedene pseudo-tokove (3c,3d), navedene tabele koje sadrže informacije neophodne za saznanje frekventnih pozicija kanala povezanih zajedno za prijenos navedenog toka (3) podataka i za identificiranje glavnog kanala.
The kit according to claim 24 wherein said standard has been generated by contacting the platform with a reference strain of E. coli bacteria (optionally E. coli ATCC 29522), and/or a reference strain of Staphylococcus aureus (optionally Staphylococcus aureus ATCC 25913). 
Kit prema zahtjevu 24 gdje je standard dobiven kontaktom platforme s referentnim sojem bakterije E. coli (po izboru E. coli ATCC 29522), i/ili s referentnim sojem Staphilococcus aureus (po izboru Staphilococcus aureus ATCC 25913).
The recombinant RSV antigen of claim 1, wherein the F1 domain comprises at least a portion of an RSV F protein polypeptide corresponding to amino acids 137-516 of the reference F protein precursor polypeptide (F0) of SEQ ID NO:2. 
Rekombinantni RSV antigen u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što domena F, sadrži u najmanju ruku dio RSV F proteinskog polipeptida koji odgovara aminokiselinama 137-516 u referentnom F proteinskom polipeptidu preteči (Fo) sa SEQ ID NO:2.
D represents a non steroidal anti-inflammatory subunit or a steroid subunit and pharmaceutically acceptable salts of the foregoing and pharmaceutically acceptable compositions containing the foregoing. 
D predstavlja nesteroidnu protuupalnu podjedinicu ili steroidnu podjedinicu, ili njenu farmaceutski prihvatljivu sol ili solvat;
A combination according to claim 1 wherein compound of formula I is selected from: 
Sastav prema zahtjevu 1 naznačen time da spoj formule I je odabran od:
treatment of squamous degeneration of macula of the eye; 
- liječenje skvamozne degeneracije makule u oku;
In the first four examples, basic formulations for sugar replacement compositions according to the present invention are given. 
U prvom od četiri primjera prikazuju se osnovne formulacije za sastavine koje zamjenjuju šećer. Te formulacije 5
A process for obtaining microcapsules 
POSTUPAK ZA DOBIVANJE MIKROKAPSULA
The process according to claim 1, wherein the drying chamber is housed in a residual-moisture dryer, and the torrefying chamber is housed in the torrefaction reactor. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se komora za sušenje nalazi u sušioniku za preostalu vlagu, a komora za torefakciju se nalazi u torefakcijskom reaktoru.
A compound of formula lyd, wherein: B represents a CyBB or HetBB; 
Spoj s formulom lyd, [image] naznačen time da: B predstavlja CYBB ili HetBB;
and R6 represent, identically or independently, a hydrogen or a C1-4 alkyl 
– R3 i R6 predstavljaju, istovjetno ili neovisno, vodik ili C1-4 alkil;
Figure 4b shows that again, the design engraved in the plate has been transferred to the soft-magnetic ink patch; the latter shows a 3-dimensional effect and a seems to move when the print is looked at from different angles. 
Slika 4b prikazuje kako je uzorak ugraviran u ploču ponovo prenesen na otisak meko magnetne tinte; potonju odlikuje 3-dimenzionalni učinak, a kada se otisak gleda iz različitih kuteva čini se kako se kreće.
heating the solution resulting from step (vi) to a temperature of 50 to 100°C for 0.15 to 30 minutes; 
zagrijavanje otopine dobivene u koraku (vi) do temperature od 50 do kroz 0.15 do 30 minuta;
Hence, a mixture of polymorphic forms of a compound frequently has different physicochemical parameters than the pure forms that comprise the mixture. 
Stoga, smjesa polimorfnih oblika spoja često ima različite fizičko-kemijske parametre nego čisti oblici koji sačinjavaju smjesu.
The method of claim 5, wherein said composition comprises a pharmaceutically acceptable carrier, diluent, or excipient. 
Postupak sukladno patentnom zahtjevu 5, naznačen time što navedeni pripravak sadrži farmaceutski prihvatljiv nosač, razrjeđivač, ili ekscipijens.
Compositions comprising trans-(−)-A9-THC, trans-(+)-A9-THC and a non-polar organic solvent useful for the Crystallizing Step can be obtained by any known or later-developed method. 
(c) kontaktiranje trans-(-)-A*-tetrahidrokanabinola iz koraka (b) sa trans-(+)-A-tetrahidrokanabinolom i nepolarnim organskim otapalom tako da formiraju prvi sastav; ili kroz
An aqueous paracetamol solution for use in perfusion according to claim 1, wherein glucose is present in a concentration between 0.5% m/v and 3.0% m/v. 
Vodena otopina paracetamola za uporabu u perfuziji sukladno patentnom zahtjevu 1, naznačena time, da je glukoza nazočna u koncentraciji između 1.0% m/v i 3.0% m/v.
A composition comprising an effective amount of at least one antibody according to any of claims 1-8 for use in a method for diagnosing or treating an IL-23 related condition in a cell, tissue, organ or animal, optionally wherein the IL-23 related condition is selected from the group consisting of psoriasis, psoriatic arthritis, Crohn's disease, multiple sclerosis, optic neuritis, and clinically isolated syndrome. 
Pripravak koji sadrži učinkovitu količinu najmanje jednog protutijela prema bilo kojem od zahtjeva 1-5 naznačen time što je za upotrebu u postupku određivanja dijagnoze ili liječenja stanja koje je povezano s IL-23 u stanici, tkivu, organu ili životinji, pri čemu je stanje koje je povezano s IL-23 odabrano iz skupine koja se sastoji od psorijaze, psorijaznog artritisa, Crohnove bolesti, multiple skleroze, optičkog neuritisa, i klinički izoliranog smdroma.
Evaporation gave a crystalline solid of the di-omeprazole magnesium salt, mp 178-180°C. 
Uparavanje je dalo kristalnu čvrstu di-omeprazol magnezij sol t.t. 178 - 180 *C.
It has also beeri shown that the metabolites of rapamycin can undergo this ester hydrolysis. 
Također je pokazano da metaboliti rapamicina mogu ući u hidrolizu estera.
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 2; and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19. 
ID BR.:2; i (f) hipervarijabilne regije lakog lanca 3 (HVR-L3) koja sadrži aminokiselinsku sekvencu SEK. ID BR.:19.
The so applied amount of adhesive was about 250 g/m2 per wood surface. 
Tako nanesena količina ljepila bila je oko 250 g/m? površine drva.
The improved disposable saliva ejector (1) according to claim 1 characterized in that said arch (7) comprises a cradle (8) adapted to longitudinally contain said second corrugated portion (6). 
Poboljšana sisaljka (1) za pljuvačku za jednokratnu upotrebu u skladu sa patentnim zahtjevom 1 naznačena time da navedeni luk (7) sadrži podlogu (8) prilagođenu da uzdužno sadrži navedeni drugi nabrani dio (6).
A constraint film according to claim 2, characterised in that the plastic polymer which is located on the surface of the front face (6a) of the supporting film (6), locally has a tension surface (Ts) having a value ranging between 45 Dyne/centimetre and 70 Dyne/centimetre. 
Film za učvršćivanje u skladu s patentnim zahtjevom 2, naznačen time, da plastični polimer na površini prednje strane (6a) nosivog filma (6) lokalno ima površinsku napetost (Ts) u rasponu vrijednosti od 45 dyna / cm do 70 dyna / cm.
The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is a polyethylene glycol linker. 
i Zo Spoj u skladu s patentnim zahtjevom 1, naznačen time, da L je polietilen glikol linker.
Process for the preparation of chelated compounds 
POSTUPAK ZA PRIPREMU KELIRANIH TVARI
is an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C3-C8) cylcoalkyl, (C3-C8) cycloalkenyl, heterocyclyl, aryl and heteroaryl. 
R7 je izborno supstituirana skupina, koju se bira između nerazgranatog ili razgranatog (C;-Cg) alkila, (C2-Cg) cikloalkila, (C3-Cg) cikloalkenila, heterociklila, arila i heteroarila.
The peptide according to claim 1 or claim 2, or the peptidomimetic according to claim 3, or the conjugate according to any one of claims 4-7 or the pharmaceutical composition of any one of claims 8-10, for use in a method for treatment of reperfusion injury in the human or animal body. 
Peptid u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 ili peptidomimetik u skladu s patentnim zahtjevom 3, ili konjugat u skladu s bilo kojim od patentnih zahtjeva 4-7 ili farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 8-10, za uporabu u metodi za liječenje reperfuzijske ozljede u ljudskom ili životinjskom tijelu.
An isolated peptide antagonist of Kv1.3 having an amino acid sequence comprising an amino acid sequence which is at least 84% identical to SEQ ID NO: 1, further comprising a substitution of glycine to isoleucine at position 10 (G10I). 
Izolirani peptidni antagonist Kv1.3 naznačen time da ima sekvencu aminokiselina koja sadrži sekvencu aminokiselina koja je barem 84% identična sa SEQ ID NO: 1, koja nadalje ima supstituciju glicina s izoleucinom u položaju 10 (G10I).
The reaction mixture was heated at 140 °C by microwave irradiation for 3.5 h. 
Reakcijska smjesa se grije na 140 *C uz mikrovalno zračenje kroz 3.5 sati.
A method of treating asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I) as claimed in claim 1, 8 or 14 or a pharmaceutically acceptable salt thereof. 
Uporaba spoja sa formulom (I) prema bilo kojem zahtjevu od 1 do 15 ili njegove farmaceutski prihvatljive soli za proizvodnju lijeka za uporabu kod liječenja astme KOPB, alergijskog rinitisa, alergijskog konjunktivitisa, atopijskog dermatitisa, raka, hepatitisa B, hepatitisa C, HIV, HPV, bakterijskih infekcija ili dermatoze.
SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 20, 31, 33 of the LC; wherein said antibody specifically binds to at least one of Ang1 and Ang2 ligands of Tie 2 receptor. 
(u) SEQ ID NO: 71 SEQID NO: 16;1 (v) SEQID NO: 71 SEQID NO: 14; pri čemu se spomenuto antitijelo ili njegov antigen-vežući fragment specifično veže za najmanje jedan od Ang-1 i Ang-2 liganda Tie-2 receptora.
Wherein optionally the compound has a formula selected from the group consisting of: 
Spoj prema zahtjevu 1 koji ima formulu odabranu iz skupine koju čine:
A dicyclohexylamine salt of compound of formula I, namely perindopril, having an X-ray powder diffraction pattern with characteristic peaks (2θ): 8.462, 10.624, 18.693, 9.424, 17.272, 14.177, 19.499, 20.765, 21.409, and 14.540. 
Dicikloheksilamin sol spoja formule I, odnosno perindoprila, koja ima uzorak difrakcije X-zraka na prahu sa slijedećim karakterističnim signalima (20): 8.462, 10.624, 18.693, 9.424, 17.272, 14.177, 19.499, 20.765, 21.409 i
p is 1. The compound of formula (I) according to claim 2, in free or salt form, wherein 
Spoj formule (1) prema zahtjevu 2, u slobodnom obliku ili u obliku soli, naznačen time, da
Embodiment 214 A method according to embodiment 213, wherein the one or more further therapeutic agents are selected from a chemotherapeutic agent, an anti-inflammatory agent, or an immunosuppressive and/or immunomodulatory agent. 
Antitijelo, imunokonjugat, bispecifična ili multispecifična molekula, farmaceutski pripravak ili vektor ekspresije za primjenu prema zahtjevu 22, naznačen time, što je jedno ili više dodatnih terapeutskih sredstava odabrano iz kemoterapijskog sredstva, protuupalnog sredstva ili imunosupresiva i/ili imunomodulatora.
in an amount from 20% to 22% by weight and the formulation further comprises: 
(b) u količini od 20% do 22% po masi i formulacija dodatno obuhvaća:
sieving a mixture of the remaining excipients, except the lubricant, through a sieve with a mesh size of not more than 1.0 mm, preferably a mesh size of 0.5 mm, 
prosijavanje smjese preostalih pomoćnih tvari, osim lubrikanta, kroz sito veličine otvora ne veće od 1.0 mm, poželjno od 0.5 mm,
Bupropion and trazodone for use in the treatment of sexual interest arousal disorder (FSAD) in a subject. 
Bupropion i trazodon naznačen time da je za uporabu za liječenje poremećaja seksualnog uzbuđenja (FSAD) kod subjekta.
• coupling the Har and Mpa residues to form a compound of formula III: 
P, je karboksilna zaštitna skupina; i * vezanje rezidua Har i Mpa radi formiranja spoja formule III:
In addition, smaller particle size tends to improve the homogeneity of powder blends, which may result in improved uniformity of the contents of the drug product. 
Dodatno, mala veličina čestica služi poboljšanju homogenosti praškastih smjesa, što može rezultirati u poboljšanoj jednoličnosti sadržaja ljekovitog produkta.
the trigger lever has at least one of a cranked and angled peripheral contour. The device as claimed in claim 1, wherein the trigger lever of the actuating element is mounted pivotably about a fixed pivot axis at one end, and has a contact region for interacting with an actuating lever at another end, and 
Plinska opruga s uređajem prema jednom ili više od zahtjeva 1 do 9, - pokretački element (4.2) s njegovim polužnim mehanizmom (5.2) razlikuje se po tome da je poluga okidača (6.2) na jednom kraju montirana zakretno oko nepomične zakretne osi (7.1), navedena poluga okidača